Drug Profile

IBI 3005

Alternative Names: IBI-3005

Latest Information Update: 10 Feb 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Innovent Biologics
Class Antineoplastics; Bispecific antibodies; Camptothecins; Drug conjugates; Immunotherapies
Mechanism of Action DNA topoisomerase I inhibitors; Hypoxia-inducible factor 1 alpha inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

08 Jan 2025 Phase-I clinical trials in Solid tumours (Metastatic disease, Inoperable/Unresectable, Late-stage disease, Second-line therapy or greater) in China (Parenteral)
22 May 2024 Innovent Biologics plans a phase I trial in Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease) (NCT06418061)
22 May 2024 Preclinical trials in Solid tumours in China (Parenteral)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com